Framework for Harmonization of Multi-Country Approval Dossiers

1. Introduction

Harmonization of multi-country approval dossiers refers to the process of standardizing the structure, scientific content, documentation, and regulatory procedures used to obtain approval for a product in multiple jurisdictions. It is particularly important in pharmaceuticals, biotechnology, medical devices, vaccines, and clinical research, where companies may need authorization from several national regulatory authorities.

The principal objective is to reduce repetitive documentation, improve regulatory efficiency, facilitate international cooperation, and maintain consistent standards of quality, safety, and efficacy.

The International Council for Harmonisation (ICH) Common Technical Document (CTD) provides a major framework for harmonizing pharmaceutical submissions. It organizes regulatory information into five modules, with Module 1 containing region-specific administrative information and Modules 2–5 providing the common scientific structure.

ICH

+1

However, harmonization does not automatically mean that approval in one country guarantees approval in another. Each country retains its legal authority to assess applications under its domestic laws.

2. Legal and Regulatory Foundations

A. Common Technical Document (CTD)

The CTD standardizes the organization of information submitted for marketing authorization. Its five modules are:

Module 1 – Administrative Information: Application forms, regional requirements, proposed product information, and legal declarations.

Module 2 – Summaries: Quality, non-clinical, and clinical overviews and summaries.

Module 3 – Quality: Manufacturing processes, product composition, specifications, stability, and quality controls.

Module 4 – Non-Clinical Study Reports: Pharmacology, toxicology, and other relevant preclinical evidence.

Module 5 – Clinical Study Reports: Clinical trial protocols, results, statistical analyses, and evidence of safety and efficacy.

This structure reduces the need to reorganize scientific evidence separately for every market. Nevertheless, the content requirements may differ between jurisdictions.

ICH

+1

B. Electronic Common Technical Document (eCTD)

The eCTD provides a standardized electronic structure for submitting and maintaining regulatory dossiers. It supports document lifecycle management, submission tracking, and the organization of amendments and supplemental information.

A harmonized electronic process should establish common document naming conventions, version control, metadata standards, validation checks, and secure transmission procedures.

C. International Regulatory Cooperation

Regulatory cooperation can take several forms:

Harmonization: Adoption of common technical standards.

Work-sharing: Multiple authorities jointly assess parts of a dossier.

Reliance: One authority gives significant weight to another trusted authority's assessment while retaining responsibility for its own decision.

Mutual recognition: Authorities formally recognize specified decisions or assessments under an applicable agreement.

The World Health Organization's good reliance practices distinguish unilateral reliance from mutual recognition and emphasize product sameness and risk-based decision-making.

Fifty-fifth report

3. Step-by-Step Framework for Harmonizing Approval Dossiers

Step 1: Identify the Applicable Legal Requirements

The applicant should prepare a country-by-country regulatory matrix identifying applicable legislation, submission formats, application fees, language requirements, clinical-trial rules, local manufacturing requirements, and pharmacovigilance obligations.

For example, an Indian pharmaceutical application may require compliance with the applicable provisions of the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and relevant CDSCO requirements. A submission in the European Union must follow the applicable EU pharmaceutical legislation and authorization procedure.

Step 2: Establish a Common Scientific Core

The applicant should prepare one controlled master dossier containing the common scientific evidence. Regional administrative documents, local labelling, country-specific safety information, and other jurisdictional requirements should be maintained as separate components.

This approach prevents inconsistent clinical summaries, manufacturing information, and safety conclusions across countries.

Step 3: Conduct a Regulatory Gap Analysis

Each target country's requirements should be compared against the master dossier. Missing documents should be classified as:

Administrative deficiencies.

Scientific or clinical evidence gaps.

Quality and manufacturing gaps.

Local legal or labelling requirements.

Additional safety or post-marketing commitments.

Step 4: Select an Appropriate Approval Pathway

Where available, applicants should consider centralized authorization, mutual recognition, decentralized procedures, or reliance pathways.

For example, the EU mutual recognition procedure is generally based on an existing national marketing authorization, whereas the decentralized procedure allows simultaneous applications in several participating Member States when the product has not yet been authorized in any of them.

Public Health

+1

Step 5: Maintain Document Control and Traceability

Every dossier should have a document owner, version number, approval date, source reference, and change history. A change to a clinical study report, manufacturing site, product formulation, or safety statement should trigger an assessment of whether the change affects applications already submitted in other jurisdictions.

Step 6: Coordinate Regulatory Questions

A central regulatory team should maintain a response tracker for questions received from different authorities. Where questions overlap, the scientific response should remain consistent, while jurisdiction-specific explanations should be added where necessary.

Step 7: Harmonize Post-Approval Obligations

Dossier harmonization must continue after authorization. Safety updates, manufacturing changes, labelling revisions, recalls, and periodic safety reporting should be assessed for their implications in every market where the product is authorized.

The WHO's good reliance practices support applying reliance throughout a product's lifecycle, provided that the sameness of the product and relevant regulatory conditions are maintained.

Fifty-fifth report

4. Important Case Laws

1. Novartis AG v. Union of India (2013), (2013) 6 SCC 1

The Supreme Court of India considered the patentability of the beta-crystalline form of imatinib mesylate, a medicine used to treat cancer. The Court upheld the rejection of the patent application under Section 3(d) of the Patents Act, 1970, because the required enhanced therapeutic efficacy had not been established.

Indian Kanoon

+1

Relevance: The case illustrates that recognition of a pharmaceutical product or its intellectual-property status in one jurisdiction does not eliminate the need to satisfy the legal requirements of another. It concerns patent law, not the harmonization of marketing authorization dossiers directly.

2. Merck Sharp & Dohme Corp. v. Comptroller-General of Patents, Designs and Trade Marks (2016), [2016] EWHC 1896 (Pat)

The English High Court examined pharmaceutical regulatory procedures, including centralized authorization, mutual recognition, and decentralized authorization within the European framework.

Bailii

Relevance: The case provides legal context for understanding how coordinated procedures operate alongside distinct regulatory requirements. Harmonized assessment procedures must be implemented according to the applicable legislation rather than treated as unrestricted automatic recognition.

3. Synthon BV v. Merz Pharma GmbH & Co. KGaA (Case C-452/06, 2008)

The Court of Justice of the European Communities considered the operation of mutual recognition under the EU pharmaceutical authorization framework. The judgment explained that recognition obligations under the relevant legislation are subject to defined procedural and legal conditions.

EUR-Lex

Relevance: This decision demonstrates that mutual recognition depends on compliance with the governing legal framework and applicable dossier requirements. It supports the principle that harmonization should operate through established legal procedures.

5. Challenges and Limitations

The major challenges include differences in national legislation, inconsistent administrative requirements, divergent interpretations of scientific evidence, translation costs, data-protection restrictions, and delays caused by repeated requests for information.

A common dossier format cannot resolve every substantive disagreement. Authorities may still require additional evidence based on local epidemiology, population characteristics, manufacturing arrangements, or public-health priorities. Intellectual-property rights and confidential commercial information must also be handled according to applicable law.

6. Conclusion

Harmonization of multi-country approval dossiers requires a common scientific structure, jurisdiction-specific legal compliance, controlled electronic documentation, coordinated regulatory communication, and consistent post-approval monitoring. The CTD and eCTD provide the technical foundation, while reliance and mutual recognition can reduce unnecessary duplication where legally available.

The case laws demonstrate that regulatory coordination must respect national legal requirements and defined recognition procedures. An effective framework should therefore pursue efficiency without compromising scientific integrity, public safety, or the independent legal responsibilities of national regulatory authorities.